Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study

被引：0

作者：

Hill, Brian T. ^{[1
]}

Torka, Pallawi ^{[2
]}

Hernandez-Ilizaliturri, Francisco ^{[2
]}

Dean, Robert ^{[1
]}

Jagadeesh, Deepa ^{[1
]}

Karamlou, Kasra ^{[1
]}

Fu, Chieh-Lin ^{[3
]}

Winter, Allison M. ^{[1
]}

Ahmed, Wesam ^{[3
]}

Smith, Mitchell ^{[1
]}

Garcia, Alex Mejia ^{[1
]}

Cooper, Brenda ^{[4
]}

Krauspe, Ethan ^{[1
]}

Zhou, Jonathan ^{[1
]}

Brooks, Taylor ^{[1
]}

Kacar, Merve ^{[1
]}

Thomas, Jenna ^{[1
]}

Li, Hong ^{[5
]}

Jia, Xuefei ^{[5
]}

Chen, Yanwen ^{[5
]}

Caimi, Paolo ^{[1
]}

机构：

[1] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA

[2] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA

[3] Cleveland Clin Florida, Weston, FL USA

[4] Univ Hosp, Cleveland Med Ctr, Cleveland, OH USA

[5] Cleveland Clin, Quantitat Hlth Sci, Cleveland, OH USA

来源：

LEUKEMIA & LYMPHOMA | 2025年

关键词：

Diffuse Large B-Cell Lymphoma; Proteosome Inhibitor; ABC (non-GC) Subtype; CHEMOTHERAPY PLUS RITUXIMAB; NON-HODGKINS-LYMPHOMA; TRANSPLANTATION; CLASSIFICATION; IBRUTINIB; SUBTYPES; TRIAL;

D O I：

10.1080/10428194.2025.2504156

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We performed a phase I/II trial to explore the safety and efficacy of carfilzomib (K) in combination with R-CHOP (KR-CHOP) in patients with diffuse large B cell lymphoma (DLBCL). A total of 48 patients were enrolled and 47 were treated. The overall response rate (ORR) was 89% (70% complete response). At a median follow-up of 31 months, 3-year Kaplan-Meier estimates of PFS and OS were 79% and 87%, respectively. Treatment with KR-CHOP for non-GC DLBCL was associated with a decreased risk of disease progression and death relative to standard of care treatment with R-CHOP with hazard ratios (HR) of 0.16 [95% confidence interval (CI) 0.04-0.58, p = 0.002] and 0.31 [(95% CI, 0.09 - 0.99), p = 0.02], respectively. The most common grade 3 or 4 adverse events (AEs) were anemia (13%), thrombocytopenia (9%) and febrile neutropenia (9%). KR-CHOP is safe and may have preferential activity in non-GC DLBCL.

引用

页数：10

共 29 条

[1] Randomized Phase II/III Study of DA-EPOCH-R plus /- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701 [J].

Abramson, Jeremy S. ;

Ruppert, Amy S. ;

Giri, Sharmila ;

Hudson, Ann ;

Hsi, Eric D. ;

Little, Richard F. ;

Gore, Steven D. ;

Vallurupalli, Anusha ;

Landsburg, Daniel J. ;

Kahl, Brad S. ;

Friedberg, Jonathan W. ;

Bartlett, Nancy L. ;

Leonard, John P. .

BLOOD, 2021, 138

[2] Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].

Alizadeh, AA ;

Eisen, MB ;

Davis, RE ;

Ma, C ;

Lossos, IS ;

Rosenwald, A ;

Boldrick, JG ;

Sabet, H ;

Tran, T ;

Yu, X ;

Powell, JI ;

Yang, LM ;

Marti, GE ;

Moore, T ;

Hudson, J ;

Lu, LS ;

Lewis, DB ;

Tibshirani, R ;

Sherlock, G ;

Chan, WC ;

Greiner, TC ;

Weisenburger, DD ;

Armitage, JO ;

Warnke, R ;

Levy, R ;

Wilson, W ;

Grever, MR ;

Byrd, JC ;

Botstein, D ;

Brown, PO ;

Staudt, LM .

NATURE, 2000, 403 (6769) :503-511

[3] Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes (vol 24, pg 679, 2018) [J].

Chapuy, Bjoern ;

Stewart, Chip ;

Dunford, Andrew J. ;

Kim, Jaegil ;

Kamburov, Atanas ;

Redd, Robert A. ;

Lawrence, Mike S. ;

Roemer, Margaretha G. M. ;

Li, Amy J. ;

Ziepert, Marita ;

Staiger, Annette M. ;

Wala, Jeremiah A. ;

Ducar, Matthew D. ;

Leshchiner, Ignaty ;

Rheinbay, Ester ;

Taylor-Weiner, Amaro ;

Coughlin, Caroline A. ;

Hess, Julian M. ;

Pedamallu, Chandra S. ;

Livitz, Dimitri ;

Rosebrock, Daniel ;

Rosenberg, Mara ;

Tracy, Adam A. ;

Horn, Heike ;

van Hummelen, Paul ;

Feldman, Andrew L. ;

Link, Brian K. ;

Novak, Anne J. ;

Cerhan, James R. ;

Habermann, Thomas M. ;

Siebert, Reiner ;

Rosenwald, Andreas ;

Thorner, Aaron R. ;

Meyerson, Matthew L. ;

Golub, Todd R. ;

Beroukhim, Rameen ;

Wulf, Gerald G. ;

Ott, German ;

Rodig, Scott J. ;

Monti, Stefano ;

Neuberg, Donna S. ;

Loeffler, Markus ;

Pfreundschuh, Michael ;

Trumper, Lorenz ;

Getz, Gad ;

Shipp, Margaret A. .

NATURE MEDICINE, 2018, 24 (08) :1290-1291

[4] Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification [J].

Cheson, Bruce D. ;

Fisher, Richard I. ;

Barrington, Sally F. ;

Cavalli, Franco ;

Schwartz, Lawrence H. ;

Zucca, Emanuele ;

Lister, T. Andrew .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :3059-+

[5] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].

Coiffier, B ;

Lepage, E ;

Brière, J ;

Herbrecht, R ;

Tilly, H ;

Bouabdallah, R ;

Morel, P ;

Van den Neste, E ;

Salles, G ;

Gaulard, P ;

Reyes, F ;

Gisselbrecht, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242

[6] Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial [J].

Davies, Andrew ;

Cummin, Thomas E. ;

Barrans, Sharon ;

Maishman, Tom ;

Mamot, Christoph ;

Novak, Urban ;

Caddy, Josh ;

Stanton, Louise ;

Kazmi-Stokes, Shamim ;

McMillan, Andrew ;

Fields, Paul ;

Pocock, Christopher ;

Collins, Graham P. ;

Stephens, Richard ;

Cucco, Francesco ;

Clipson, Alexandra ;

Sha, Chulin ;

Tooze, Reuben ;

Care, Matthew A. ;

Griffiths, Gareth ;

Du, Ming-Qing ;

Westhead, David R. ;

Burton, Catherine ;

Johnson, Peter W. M. .

LANCET ONCOLOGY, 2019, 20 (05) :649-662

[7] Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up [J].

Davies, Andrew J. ;

Barrans, Sharon ;

Stanton, Louise ;

Caddy, Josh ;

Wilding, Sam ;

Saunders, Geoff ;

Mamot, Christoph ;

Novak, Urban ;

McMillan, Andrew ;

Fields, Paul ;

Collins, Graham P. ;

Stephens, Richard ;

Cucco, Francesco ;

Sha, Chulin L. ;

van Hoppe, Moniek ;

Tooze, Reuben ;

Davies, John R. ;

Griffiths, Gareth ;

Schuh, Anna ;

Burton, Catherine ;

Westhead, David R. ;

Du, Ming-Qing ;

Johnson, Peter W. M. .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (15) :2718-+

[8] Risk factors for cardiovascular events and mortality in patients diagnosed with diffuse large B-cell lymphoma and treated with anthracyclines [J].

Diamond, Akiva ;

Ayyappan, Sabarish ;

Cao, Shufen ;

Tashtish, Nour ;

Boughan, Kirsten ;

Cooper, Brenda ;

Fu, PingFu ;

Caimi, Paolo F. .

HEMATOLOGICAL ONCOLOGY, 2022, 40 (04) :626-636

[9] Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray [J].

Hans, CP ;

Weisenburger, DD ;

Greiner, TC ;

Gascoyne, RD ;

Delabie, J ;

Ott, G ;

Müller-Hermelink, HK ;

Campo, E ;

Braziel, RM ;

Jaffe, ES ;

Pan, ZG ;

Farinha, P ;

Smith, LM ;

Falini, B ;

Banham, AH ;

Rosenwald, A ;

Staudt, LM ;

Connors, JM ;

Armitage, JO ;

Chan, WC .

BLOOD, 2004, 103 (01) :275-282

[10] Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind? [J].

Khurana, Arushi ;

Mwangi, Raphael ;

Nowakowski, Grzegorz S. ;

Habermann, Thomas M. ;

Ansell, Stephen M. ;

LaPlant, Betsy R. ;

Link, Brian K. ;

Cerhan, James R. ;

Maurer, Matthew J. ;

Witzig, Thomas E. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15) :1641-+

← 1 2 3 →